Decision
Lumasiran in the treatment of primary hyperoxaluria type 1 (PH1) in all age groups
EAMS scientific opinion issued to Alnylam UK Limited for lumasiran in the treatment of primary hyperoxaluria type 1 (PH1) in all age groups.
Documents
PDF, 138 KB, 3 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 2.2 MB, 12 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 1.45 MB, 5 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 2.64 MB, 3 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
PDF, 115 KB, 4 pages
This file may not be suitable for users of assistive technology.
Request an accessible format
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email
webupdates@mhra.gov.uk. Please tell us what format you need. It will help us if you say what assistive technology you use.
Details
The scientific opinion includes:
- a public assessment report (PAR)
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
- Information for NHS Medical Directors
For new patients wishing to access EAMS medicines in England, trusts must register patients on the NHS England web-based registration system. Queries to NHS England regarding the scheme can be submitted to england.eams@nhs.net.
For information about access in Northern Ireland, contact Chief Pharmaceutical Officer and Joe Magee, Secondary Care Directorate at Joe.Magee@dhsspsni.gov.uk.
For information about access in Scotland contact the Scottish Government Directorate General Health & Social Care at medicines.policy@gov.scot
For information about access in Wales, contact the Welsh Government Health and Social Services Group by emailing Andrew Evans, Chief Pharmaceutical Officer or Lynne Schofield, Head of Pharmacy and Prescribing policy at Pharmacyand.PrescribingBranch@gov.wales
Updates to this page
Published 14 July 2020